Trials / Terminated
TerminatedNCT04408599
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- NextCure, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NC410 | NC410 is an experimental antibody drug that may make the immune response more active against cancer |
Timeline
- Start date
- 2020-06-10
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
- First posted
- 2020-05-29
- Last updated
- 2024-07-25
- Results posted
- 2024-07-25
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04408599. Inclusion in this directory is not an endorsement.